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ABSTRACT
Chimeric antigen receptor (CAR) T-cells have shown great promise in the treatment of B-cell malig-
nancies. For acute myeloid leukemia (AML), however, the optimal target surface antigen has yet to be
discovered. Alternatively, T-cell receptor (TCR)-redirected T-cells target intracellular antigens, marking
a broader territory of available target antigens. Currently, adoptive TCR T-cell therapy uses peripheral
blood lymphocytes for the introduction of a transgenic TCR. However, this can cause graft-versus-host
disease, due to mispairing of introduced and endogenous TCR chains. Therefore, we started from
hematopoietic stem and progenitor cells (HSPC), that do not express a TCR yet, isolated from healthy
donors, patients in remission after chemotherapy and AML patients at diagnosis. Using the OP9-DL1
in vitro co-culture system and agonist selection, TCR-transduced HSPC develop into mature tumor
antigen-specific T-cells with only one TCR. We show here that this approach is feasible with adult
HSPC from clinically relevant sources, albeit with slower maturation and lower cell yield compared to
cord blood HSPC. Moreover, cryopreservation of HSPC does not have an effect on cell numbers or
functionality of the generated T-cells. In conclusion, we show here that it is feasible to generate TA-
specific T-cells from HSPC from adult healthy donors and patients and we believe these T-cells could be
of use as a very valuable form of patient-tailored T-cell immunotherapy.
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The last few years there’s been increasing evidence that T-cell-
based immunotherapy is a successful treatment option for
hematologic malignancies. Chimeric antigen receptor (CAR)
T-cells are derived from a patient’s own immune cells and are
able to recognize and target surface antigens independent of
HLA. Most success has been achieved targeting CD19 in
B-cell malignancies.1,2 For acute myeloid leukemia (AML),
a suitable target surface antigen would ideally be expressed
on leukemic blasts and also leukemic stem cells (LSC), which
are often deemed responsible for relapse,3 and not on indis-
pensable normal hematopoietic cells. This target antigen,
however, has yet to be discovered. (Pre)clinical studies target-
ing CD44v6,4 CLL1,5 FLT3,6 LeY,7 NKG2D ligands,8,9 CD33
and/or CD12310-12 frequently show on-target off-leukemia
cytotoxicity. Another problem arising with targeting cell sur-
face antigens is antigen downregulation, leading to escape and
subsequent disease recurrence.13,14
Using a different approach, T-cell receptor (TCR)-modified
T-cell therapy targets intracellular antigens which are often
essential for cellular and/or oncogenic function and are there-
fore less prone to antigen escape. In TCR T-cell therapy,
peripheral blood T-lymphocytes (PBL) are isolated and geneti-
cally engineered to express a transgenic TCR. Clinical trials
with a TCR targeting Wilms’ tumor 1 (WT1), a tumor antigen
overexpressed in a variety of cancers, including AML (in 80%
of patients15), have already been initiated.16–19 In this approach,
however, mispairing can occur between the endogenous and
the introduced TCRα and TCRβ chains, leading to off-target
toxicities.20,21 Moreover, intensive in vitro culturing of PBL
potentially leads to exhausted TEFF/TEM T-cells with limited
effector function and in vivo persistence,22,23 while it has
been shown that less differentiated TN, TCM and especially
TSCM are the most potent antitumor T-cells for T-cell
immunotherapy.24–26
Multiple strategies are being explored to circumvent mis-
pairing of TCR chains and extensive ex vivo culturing of
T-cells. One strategy generates tumor antigen (TA)-specific
T-cells by TCR transduction of induced pluripotent stem
cells.27 Another strategy, developed in our group, generates
TA-specific T-cells with a single TCR and naive-like charac-
teristics from TCR-transduced postnatal thymus28 and cord
blood (CB;29) hematopoietic stem and progenitor cells
(HSPC). This strategy is based on the OP9-DL1 in vitro co-
culture system and agonist selection to induce T-cell differ-
entiation from HSPC.
Here, we wanted to evaluate clinically more relevant HSPC
sources in our model and generated functional, TA-specific
T-cells from adult HSPC sources: healthy donors, patients in
remission after chemotherapy, and AML patients at diagnosis.
We show that this approach is feasible, both from healthy
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donors and patients, from fresh as well as cryopreserved
samples, albeit with slower maturation and lower cell num-
bers as compared to cord blood HSPC.
Materials and methods
Isolation of human CD34+ cells
We collected cord blood, mobilized peripheral blood from
patients undergoing autologous hematopoietic stem cell trans-
plantation (HSCT) and from healthy donors for allogeneic
HSCT, and peripheral blood, bone marrow, and leucapheresis
from AML patients at diagnosis, with a CD34-negative AML.
These samples were obtained and used following guidelines of
the Medical Ethical Committee of the Ghent University
Hospital. Informed consent was obtained in accordance with
the Declaration of Helsinki.
Agonist peptide stimulation of HLA-A2 positive samples
Agonist peptide stimulation was carried out as described in
Snauwaert et al.28 In brief, cells were harvested fromOP9-DL1 co-
culture and seeded in tissue culture plates (BD Biosciences) in
IMDM (Thermo Fisher Scientific, 12440053) supplemented with
10% fetal calf serum (FCS; Bovogen, SFBS-FR), 2 mM
L-glutamine (Thermo Fisher Scientific, 25030–081), 100 IU/ml
penicillin, and 100 IU/ml streptomycin (Thermo Fisher Scientific,
15140–122) (complete IMDM, cIMDM) with 10 ng/ml interleu-
kin 7 (IL-7; R&D Systems, 207-IL-025) and 10 µg/ml relevant
WT1126−134 agonist peptide (Anaspec by Eurogentec, custom
peptide). Cells were harvested after 5–6 days and maturation
was assessed by flow cytometry, as upregulation of CD27 and
downregulation of CD1a. If necessary, cells were subjected to
agonist peptide stimulation in the following rounds (maximum
3 rounds).
Cell-line dependent maturation of HLA-A2 negative
samples
For HLA-A2 negative HSPC, maturation was obtained using co-
culture with irradiated peptide-pulsed T2 cells. T2 cells were
pulsed for 4 h with WT1126−134 peptide and irradiated (40 Gy).
T-cell precursors were harvested from OP9-DL1 and seeded in
tissue culture plates in cIMDM with 10 ng/ml IL-7. T2 cells were
added at a 4/1 effector/target (E/T) ratio. Cells were harvested
after 5–6 days and maturation was assessed by flow cytometry. If
necessary, cells were stimulated with freshly peptide-pulsed and
irradiated T2 cells in consecutive rounds (maximum 3 rounds).
Statistics
Statistical analyses were performed in Prism v5.01 (GraphPad
Software), using statistical tests as indicated in figure legends.
Results were considered statistically significant when P-value
was less than 0.05.
Additional materials and methods are provided in
Supplemental Data.
Results
CD34+ hematopoietic stem and progenitor cells from adult
sources show slower in vitro maturation kinetics and less
expansion compared to neonatal cord blood HSPC
We wanted to investigate the possibility of in vitro generation
of TA-specific T-cells from clinically relevant HSPC sources,
following the protocol previously described by our group.28,30
CD34+ HSPC were isolated from mobilized peripheral blood
(mPB) samples from healthy donors (n = 13), mPB samples
from patients in remission after chemotherapy (n = 16), and
samples (bone marrow, peripheral blood, or leukapheresis)
from AML patients at diagnosis, with CD34-negative AML
(n = 13). Patient characteristics are shown in Supplementary
Table S1.
We co-cultured isolated CD34+ HSPC from patient and
healthy donor samples on OP9-DL1 cells until a significant
population (50–80%) showed lymphoid lineage commitment,
as evidenced by the combined surface expression of CD5 and
CD7. With cord blood (CB) HSPC, this is generally at day 14
after initiation of co-culture. With adult HSPC sources (both
patient and healthy), however, the kinetics to obtain a robust
CD5+CD7+ population appeared to be slower (Figure 1(a) and
Supplementary Figure S1).
Healthy donor relative cell numbers were similar to those
of CB at day of transduction (d14 for CB, d19 or 24 for
healthy donors) (Figure 1(b)). Patient cells, however, showed
lower overall expansion rates (Figure 1(b)). At day 14, sig-
nificant differences in cell numbers could be observed
between the different sample populations: fewer cells were
generated from patient samples as compared to healthy
donor samples, with patients in remission doing significantly
better than AML patients at diagnosis (Figure 1(c)). At later
timepoints (d19 and d24), the differences in relative cell
numbers between adult sample populations remain significant
(data not shown). Also, the relative cell yield at the end of the
in vitro T-cell generation process, both before (Supplementary
Figure S2A) and after (Supplementary Figure S2B) polyclonal
feeder expansion, was significantly lower for co-cultures
started from patient HSPC, as compared to healthy donor
HSPC.
Since the healthy donors in our study were significantly
younger compared to patients (Supplementary Table S1 and
Supplementary Figure S3), we investigated if there was an
effect of donor age on cell numbers. In our experiments, no
significant correlation between age and cell numbers was
observed at day 14 (Supplementary Figure S4) nor at later
timepoints (data not shown).
To further in-depth characterize the isolated CD34+ starting
population, we analyzed the presence of different progenitor
populations within the CD34+ population: hematopoietic stem
cells (HSC, lin−CD34+CD38lo/-CD45RA−CD90+), multipotent
progenitors (MPP, lin−CD34+CD38lo/-CD45RA−CD90−), multi-
lymphoid progenitors (MLP, lin−CD34+CD38lo/-CD45RA+
CD90−) and early T-progenitors (ETP, lin−CD34+CD38+
CD7+).31 Flow cytometric analysis revealed a higher percentage
of early T-progenitors in CB HSPC as compared to adult HSPC
(Figure 2). No relevant differences in other progenitor fractions
were observed. These data can explain faster maturation kinetics
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for CB, as compared to adult sample populations, but not differ-
ences between adult populations.
Multiple rounds of agonist peptide stimulation are
needed to achieve the selection and maturation of HSPC
from adult sources
When a large population of lymphoid-committed cells was
present (50–80%), cells were transduced with a TA-specific
TCR. At this point, intracellular CD3 was present. Here, we
used the WT1-specific TCR, recognizing the HLA-A2-
restricted peptide WT1126−134. Median transduction effi-
ciency, measured 2 days after transduction, was 17.6%
(range 10.2–27.7%), with donor-specific variations indepen-
dent of sample group (data not shown).
Upon additional OP9-DL1 co-culture, TCR-transduced cells
showed further T-lineage differentiation toward CD4+CD8+
double positive (DP) cells. At this stage, maturation to mature
single positive T-cells can be obtained through agonist selection,
as described by Snauwaert et al.28 Briefly, for co-cultures from
HLA-A2+ samples, the cognate peptide recognized by the trans-
genic TCR was added and cross-presented to inducematuration,
as illustrated by transition from a CD27−CD1a+ to a CD27+-
CD1a− (mature) phenotype. For CB samples, the majority of the
cells were CD1a− 6 days after agonist selection (Figure 3(a)). For
co-cultures started from adult HSPC sources, however, only
a small percentage was CD27+ and CD1a− at this timepoint.
Therefore, cells were harvested and again subjected to agonist
peptide stimulation. This process was repeated until approxi-
mately 30% of the cells were CD27+CD1a−. For co-cultures from
healthy donor samples, 1 to 2 rounds of agonist peptide stimula-
tion were needed to reach this point (Figure 3(b)). For co-
cultures from patients in remission and from AML patients at
diagnosis, up to 3 rounds were needed (Figure 3(c,d)). However,
Figure 1. CD34+ HSPC from adult sources show slower in vitro maturation kinetics and less expansion compared to cord blood HSPC. (a) Culture protocol. Numbers
indicate time (in days) of co-culture. Abbreviations: CB, cord blood; mPB, mobilized peripheral blood; BM, bone marrow; DP, double positive; SCF, stem cell factor;
FLT3-L, FLT3 ligand; IL, interleukin; RV, retroviral. (b) Kinetics of expansion before transduction in OP9-DL1 co-cultures of HSPC from cord blood (n = 7), healthy
donors (n = 12), patients in remission after chemotherapy (n = 15) and AML patients at diagnosis (n = 12). Mean ± s.d. is shown. T-cell committed progenitors in cord
blood co-cultures were transduced at day 14, in co-cultures from adult HSPC at later timepoints (d19 or d24). (c) Relative cell numbers (i.e. cell numbers obtained
when theoretically starting from a single CD34+ cell at day 0) at day 14 of co-cultures from cord blood (n = 7), healthy donor (n = 13), patient in remission after
chemotherapy (n = 16) and AML patient at diagnosis (n = 13) HSPC. Values for individual samples and mean ± s.d. are shown. Mann–Whitney U test was used to
assess statistical significance. P-value < 0.05 (*), P < 0.01 (**) and P < 0.001 (***).
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percentages of 60–70% CD27+CD1a− cells, as obtained in CB,
were never reached in co-cultures from adult HSPC sources
despite multiple rounds of agonist peptide stimulation.
To make sure that the continued maturation we observed in
adult samples with successive rounds of agonist peptide stimula-
tion was due to upregulation of CD27 by remaining CD1a+CD27−
DP cells, and not to proliferation of already present CD27+ cells,
we sorted the remainingCD27− cells after the first roundof agonist
peptide stimulation and subjected these to another round of
agonist peptide stimulation. These experiments confirmed addi-
tional maturation of CD27− cells with subsequent rounds of ago-
nist peptide stimulation (data not shown).
Phenotype of in vitro generated TA-specific T-cells shows
Tscm-like characteristics and largely lacks PD-1 expression
Some T-cell subsets are superior over others for use in adop-
tive T-cell immunotherapy. Especially more naive subsets (TN,
TSCM, TCM) have been shown to exert a higher therapeutic
efficiency.24,25 For this reason, we analyzed the phenotype of
our in vitro generated T-cells, both after (every round of)
agonist peptide stimulation and after polyclonal feeder expan-
sion. T-cells were stained with various phenotypic markers
(CD62L, CXCR3, CD56, NKG2D, CD57, CD95, CD127,
CD45RA, CD45RO) and analyzed using flow cytometry.
Since PD-1 was demonstrated to be a marker of T-cell
exhaustion,32 we also evaluated PD-1 expression.
Repetitive antigen stimulation is known to lead to a skewed
effector memory (TEM) phenotype, with ensuing lower ther-
apeutic efficacy.33 Therefore, we first evaluated the effect of
multiple rounds of agonist peptide stimulation on the pheno-
type of the cells. We compared cells that had been exposed to
agonist peptide just once to cells that had undergone multiple
rounds of agonist peptide stimulation. Altogether, we
observed significant downregulation of CXCR4 and PD-1,
and a trend toward upregulation of CXCR3 and CD45RO
after repeated agonist peptide stimulation, a phenotype more
skewed toward TEM/TTE (Supplementary Figure S5).
Combining CD62L, CD45RA, CD95 and CXCR3 staining to
identify T-cell subpopulations,34 we observed
a downregulation in the percentage of cells with a TN pheno-
type (CD45RA+ CD62L+ CXCR3− CD95−) and an upregula-
tion in TTE cells (CD45RA
+ CD62L− CXCR3− CD95+) after
multiple rounds of agonist peptide stimulation (Figure 4(a)),
consistent with the separate stain data displayed in
Supplementary Figure S5.
After agonist peptide-induced maturation, cells were
polyclonally expanded on irradiated feeder cells, for
a median of 12 days (range 10–14 days), to obtain pheno-
typically and functionally mature TA-specific T-cells. After
polyclonal expansion, simultaneous staining with CD62L,
CD45RA, CD95, and CXCR3 revealed an average of 33%
of cells with a TSCM phenotype (CD45RA
+ CD62L+
CXCR3+ CD95+)34 (Figure 4(b)). More extensive staining
further confirmed TSCM characteristics: CD57
− CD45RO+
(Supplementary Figure S6).34 CD62L expression was
slightly downregulated as compared to expression after
agonist peptide stimulation (50–60% and 80–90% of cells,
respectively), which could be due to T-cell activation.35
Moreover, cells upregulated expression of CXCR3, CD56
and NKG2D, additional markers of T-cell activation (cells
were CD56−NKG2D− after agonist selection, data not
shown).28,36,37 Almost all cells showed CD95 expression,
both before and after polyclonal feeder expansion
(Supplementary Figure S5 and S6), which seems to be
inherent to our in vitro OP9-DL1 co-cultures. CD127 (IL-
7Rα) expression, another marker for TSCM,
34 could not be
observed, both after agonist selection and after polyclonal
expansion (data not shown and Supplementary Figure S6).
The T-cell exhaustion/activation marker PD-1,32,38 pre-
sent after agonist selection, declined after polyclonal expan-
sion in absence of the cognate antigen. Percentages of PD-1+
mature T-cells ranged from 1.1% to 42% (average 11.6%),
marking donor-dependency (Figure 4(c)). Furthermore,
T-cells generated from healthy donor HSPC had
a significantly lower PD-1 expression compared to T-cells
from patient HSPC. This difference in PD-1 expression
Figure 2. Presence of early T-progenitors at the start of co-cultures. Percentage of
early T-progenitors (ETP, lin− CD34+ CD38+ CD7+) in CD34+ cells isolated at day 0 of
co-cultures from cord blood (n = 7), healthy donors (n = 7), patients in remission
(n = 5) and AML patients at diagnosis (n = 9). Individual samples, mean percentages
per sample group and s.d. are shown. Mann–Whitney U test was used to assess
statistical significance. P-value < 0.01 (**). Other differences were not significant.
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between healthy donors and patients was independent of age
(data not shown).
We compared the phenotype of our in vitro generated TA-
specific T-cells to TCR-transduced PBL. For this, PBL were
isolated, stimulated, transduced with a TA-specific TCR and
polyclonally expanded on irradiated feeder cells. Staining with
CD62L, CD45RA, CD95, and CXCR3 showed that the major-
ity of the cells had a TN phenotype after isolation
(Supplementary Figure S7). After stimulation, transduction,
and subsequent polyclonal feeder expansion, 14.62% of TCR-
transduced PBL showed a TSCM phenotype, 13.55% a TCM
phenotype, 9.83% a TEM phenotype and 1.5% a TTE pheno-
type (Supplementary Figure S7).
In vitrogenerated TA-specific T-cells specifically recognize
and kill TA-expressing cell lines
To investigate the functionality of in vitro generated WT1-
specific T-cells from adult HSPC, T-cells were cultured with
THP-1, a HLA-A2+WT1+ cell line, and JY cells (HLA-A2+
WT1−), as a negative control. Interferon-gamma (IFNɣ) pro-
duction after recognition of WT1+ target cells was measured
through intracellular staining. In vitro generated T-cells, both
from patient and healthy donor samples, specifically recog-
nized WT1-presenting cells and, as a result, produced IFNɣ
(median 12.85% of cells, range 4–48%) (Figure 5(a)). No
significant difference could be observed in IFNɣ production
Figure 3. Multiple rounds of agonist peptide stimulation are needed to achieve the selection and maturation of HSPC from adult sources. Maturation of TCR-
transduced cells after one or more rounds of agonist peptide stimulation. Contour plots show CD1a (x-axis) and CD27 (y-axis) expression before agonist stimulation
and after 1, 2 or 3 rounds of agonist stimulation for TCR-transduced cells in co-cultures from cord blood (a), healthy donors (b), patients in remission after
chemotherapy (c) and AML patients at diagnosis (d). Gating on eGFP+ TCR-transduced cells. Numbers indicate percentages of cells in each quadrant. A representative
sample from each sample group is shown.
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between T-cells generated from healthy donor versus patient
HSPC. Percentages of IFNɣ+ cells are in line with CB-derived
T-cells (data not shown). We compared WT1-specific T-cells
generated in vitro from adult HSPC, with WT1-specific
T-cells generated from PBL. Whereas aspecific aCD3/aCD28
stimulation led to similar percentages of IFNɣ+ cells (median
42.93% of cells, range 10.95–82.3% for HSPC and median
46.02% of cells, range 26.5 – 56% for PBL), specific recogni-
tion of WT1+ target cells was significantly lower in PBL-
derived T-cells (median 1.51% of cells, range 0.85–2.2%)
(Figure 5(a)).
Furthermore, specific lysis of target cell lines was determined
using a 51chromium release assay. For this, T2 cells were pulsed
with relevant WT1 or irrelevant influenza peptide, and the HL-
60-A2 cell line was used as an additional HLA-A2+WT1+ target
(qPCR showed higher WT1 expression on HL-60-A2 compared
to THP-1, data not shown). An average of 35.7% (range 5.1–
87.8%) of HLA-A2+WT1+ cells were killed, whereas HLA-A2+
WT1− cells were killed only to a minimal extent (Figure 5(b)).
T-cells generated from HSPC from AML patients at diagnosis
tended to lyse a smaller percentage of target cells, but differences
were not significant. PBL-derivedWT1-specific T-cells were able
to kill only small percentages of HLA-A2+WT1+ target cells
(4.34% of cells on average) (Figure 5(b)).
It has been shown that exposing maturing T-cells multiple
times to antigen, as we did with the repeated agonist peptide
stimulation, could lead to exhaustion and diminished
functionality.39,40 Therefore, we evaluated the effect of multiple
agonist peptide stimulations, in reference to only one stimula-
tion, on the functionality of resulting T-cells. While repetitive
antigen stimulation did seem to have a (minor) effect on phe-
notype, no significant differences could be found regarding the
functionality of the cells. IFNɣ production after 3 rounds of
agonist peptide stimulation appeared lower, but differences
were not significant (Supplementary Figure S8A). 51Chromium
release assays revealed no differences in lysis of HLA-A2+WT1+
targets (Supplementary Figure S8B).
Cryopreservation has a negligible effect on maturation
kinetics and functionality of in vitro generated
TA-specific T-cells
The CD34+ HSPC pool of patients can be damaged by che-
motherapy and other treatments, rendering a stem cell harvest
difficult. Therefore, we investigated the possibility of collect-
ing HSPC beforehand at a time of remission, and cryopreser-
ving them for longer periods of time, before generating TA-
specific T-cells for therapy. Also, cryopreserved healthy donor
Figure 4. Phenotype of in vitro generated T-cells after agonist peptide stimulation and after polyclonal feeder expansion. (a) Percentage of cells with a TN (CD45RA
+
CD62L+ CXCR3− CD95−), TSCM (CD45RA
+ CD62L+ CXCR3+ CD95+), TCM (CD45RA
− CD62L+ CXCR3+ CD95+), TEM (CD45RA
− CD62L− CXCR3− CD95+) and TTE (CD45RA
+
CD62L− CXCR3− CD95+) phenotype before agonist peptide stimulation, and after 1, 2 or 3 rounds of agonist peptide stimulation. (b) Percentage of cells with a TN,
TSCM, TCM, TEM, and TTE phenotype after polyclonal feeder expansion. For (a) and (b) T-cells were generated from HSPC from healthy donors (n = 3), patients in
remission (n = 6) and AML patients at diagnosis (n = 3). Gating on eGFP+ TCR-transduced cells. Mean and s.d. are shown. (c) Percentage of cells positive for PD-1
expression after polyclonal feeder expansion. T-cells were generated from HSPC from healthy donors (n = 8), patients in remission after chemotherapy (n = 9) and
AML patients at diagnosis (n = 6). Gating on eGFP+ TCR-transduced cells. Individual samples and mean ± s.d. are shown. Mann–Whitney U test was used to assess
statistical significance. P-value < 0.05 (*).
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HSPC could be used for the generation of off-the-shelf T-cells
for cancer therapy, and for donor-derived adoptive T-cell
therapy after haploidentical HSCT. We evaluated the effect
of cryopreservation both on maturation kinetics of T-cell
precursors in OP9-DL1 co-cultures, and functionality of the
resulting mature T-cells.
After sample collection and density gradient centrifuga-
tion, part of the cells was frozen and part of the cells used
for further CD34+ HSPC isolation and ‘fresh’ OP9-DL1 co-
culture. Cryopreserved cells were thawed, CD34+ cells were
isolated and cultured on OP9-DL1. We compared the relative
cumulative expansion of fresh and frozen HSPC from CB,
healthy donors, and patients (both in remission and at diag-
nosis) (Supplementary Figure S9A). At day 14, no notable
differences in relative cell numbers could be found between
fresh and frozen HSPC (Figure 6(a)). Also, relative cell yield
of mature T-cells at the end of co-cultures, both before
(Supplementary Figure S9B) and after (Supplementary
Figure S9C) polyclonal feeder expansion, was similar for
T-cells generated from fresh and frozen HSPC.
At the end of the in vitro culture protocol, function-
ality experiments revealed significantly higher IFNɣ pro-
duction after HLA-A2+WT1+ target recognition by T-cells
generated from fresh samples as compared to cryopre-
served samples (Supplementary Figure S10). However,
lysis of target cell lines appeared unaffected by cryopre-
servation (Figure 6(b)).
Mature TA-specific T-cells can also be generated from
HSPC of HLA-A2 negative healthy donors
To try and circumvent HLA restrictions incurred by the use of
a transgenic TCR, we wanted to investigate whether it would
be possible to generate HLA-A2-restricted TA-specific T-cells
to administer to a HLA-A2+ patient, starting from CD34+
cells from HLA-A2− donors. Agonist peptide cross-
presentation, to obtain maturation from CD1a+CD27− TCR-
transduced DP cells to CD1a−CD27+ SP cells,28 is not possible
with HLA-A2− samples due to HLA-restriction of the TCR.
Snauwaert et al. demonstrated that the addition of HLA-A2+
dendritic cells (DC) together with the agonist peptide to HLA-
A2− co-cultures results in T-cell maturation.28 To optimize
this protocol, we excluded the possibility of other peptides
being presented on the surface of the DC, by using the
transporter associated with antigen processing (TAP)-
deficient HLA-A2+ T2 cell line as antigen-presenting cells.
T2 cells fail to present endogenous peptides and can be loaded
with exogenously administered peptides. At the DP stage, we
added the T2 cell line pulsed with the agonist peptide in co-
cultures from HLA-A2− HSPC. Subsequent downregulation of
CD1a expression could be observed, in accordance with our
observations for HLA-A2+ DP cells (data not shown).
However, upregulation of CD27 does not occur, probably
due to the binding of CD27 on T-cell precursors with CD70
expressed by T2 cells (data not shown).
Figure 5. In vitro generated TA-specific T-cells specifically recognize and kill TA-expressing cell lines. (a) Intracellular staining of T-cells for interferon-gamma (IFNg)
after co-culture with THP-1 (HLA-A2+ WT1+) or JY (HLA-A2+ WT1−) cells. Culture medium was used as a negative control, stimulation with aCD3/aCD28 as a positive
control. Effector/target ratio 1/2. Gating on eGFP+ TCR-transduced cells. T-cells generated from HSPC from healthy donors (n = 4), patients in remission after
chemotherapy (n = 5), AML patients at diagnosis (n = 4) and PBL (n = 6). (b) Percentage specific lysis determined via 4-h 51chromium release assay after co-culture of
T-cells with T2 cells pulsed with relevant WT1 or irrelevant influenza (INF) peptide (10 µg/ml), HL-60-A2 (HLA-A2+ WT1+), THP-1, or JY cells. Effector/target ratio 10/1.
T-cells generated from HSPC from healthy donors (n = 6), patients in remission after chemotherapy (n = 7), AML patients at diagnosis (n = 8) and PBL (n = 6). For (a)
and (b) mean and s.d. are shown. Kruskal–Wallis test was used to determine statistical significance between different HSPC sample groups. Differences were not
significant. Mann–Whitney U test was used to determine statistical significance for between-group comparisons for HSPC- and PBL-derived T-cells. P-value < 0.05 (*)
and P < 0.01 (**).
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Although phenotypic analysis of mature TA-specific T-cells
demonstrated significantly higher CD62L expression in HLA-
A2− as compared to HLA-A2+ donor-derived T-cells, overall
phenotype remained similar (Supplementary Figure S11A).
Comparing the functionality of TA-specific T-cells gener-
ated from HLA-A2+ and HLA-A2− HSPC, we found no sig-
nificant differences in IFNγ production after recognition of
HLA-A2+WT1+ target cells (Supplementary Figure S11B).
Also, 51chromium release assays showed no difference in kill-
ing of target cell lines (Figure 7), indicating that it is possible
to generate functional TA-specific T-cells, recognizing the TA
in a HLA-A2+ context, from both HLA-A2+ and HLA-A2−
donors.
Discussion
We have shown that it is feasible to generate functional TA-
specific T-cells from clinically relevant stem cell sources, using
the OP9-DL1 in vitro co-culture system and agonist
selection.28 T-cell differentiation kinetics from adult HSPC
sources were slower compared to the kinetics of CB samples.
These results are in line with a publication by Offner and
colleagues, who found that bone marrow (BM)-derived HSPC
from older (>40 years) donors had a lower capacity to reach
the CD4+CD8+ double-positive stage of T-cell differentiation
in fetal thymic organ cultures, as compared to HSPC from
younger donors.41 This indicates an impact of donor age on
T-cell generation capacity (in vitro). We did, however, not
find a significant correlation between age and cell numbers.
A possible explanation could be the limited age range within
sample groups, with healthy donors being mostly younger
(<40 years) and patients being older (>40 years). Healthy
donor-derived T-cells possessing only one TA-specific TCR
could be used in the context of HSCT, even after haploiden-
tical HSCT, thereby avoiding graft-versus-host disease
(GVHD) caused by a partial HLA mismatch.42
In patients, chemotherapy has been shown to have
a detrimental effect on T-cells. Total CD8+ lymphocyte counts
restore within three to 6 months after cessation of cytotoxic
therapy, whereas CD4+ T-cells suffer a prolonged lymphope-
nia, resulting in T-cell subset inversed ratio and repertoire
skewing.43 As T-cell-based immunotherapy is currently posi-
tioned for high-risk patients after several lines of (chemo)
Figure 6. Cryopreservation has a negligible effect on maturation kinetics and the functionality of in vitro generated TA-specific T-cells. (a) Relative cell numbers at day
14 of co-cultures (day at which cord blood progenitors were transduced) from fresh and cryopreserved (frozen) HSPC from cord blood (n = 6), healthy donors (n = 6),
patients in remission after chemotherapy (n = 7) and AML patients at diagnosis (n = 6). Individual fresh and paired frozen samples are shown. (b) Percentage specific
lysis determined via 4-h 51chromium release assay after co-culture of T-cells with T2 cells pulsed with relevant WT1 or irrelevant influenza (INF) peptide (10 µg/ml),
HL-60-A2 (HLA-A2+ WT1+), THP-1 (HLA-A2+ WT1+) or JY (HLA-A2+ WT1−) cells. Effector/target ratio 5/1. T-cells generated from fresh and cryopreserved (frozen) HSPC
(n = 11). Results from different sample groups (healthy donors, patients in remission and AML patients at diagnosis) were pooled. Mean and s.d. are shown. Wilcoxon
matched-pairs signed-rank test was used to assess statistical significance. Differences were not significant.
Figure 7. Functional TA-specific T-cells can also be generated from HSPC from
HLA-A2 negative donors. Percentage specific lysis determined via 4-h
51chromium release assay after co-culture of T-cells with T2 cells pulsed with
relevant WT1 or irrelevant influenza (INF) peptide (10 µg/ml), HL-60-A2 (HLA-A2+
WT1+), THP-1 (HLA-A2+ WT1+) or JY (HLA-A2+ WT1−) cells. Effector/target ratio
5/1. Mean and s.d. are shown. T-cells generated from HLA-A2+ (n = 5) and HLA-
A2− (n = 4) HSPC. Results from different sample groups (healthy donors, patients
in remission and AML patients at diagnosis) were pooled. Mann-Whitney U test
was used to assess statistical significance. Differences were not significant.
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therapy, we wanted to evaluate the generation of TA-specific
T-cells from HSPC isolated from patients in remission. We
show that the heavy pre-treatment of these patients resulted in
slower T-cell differentiation of isolated HSPC in OP9-DL1 co-
cultures, and the need for multiple rounds of agonist peptide
stimulation to reach a phenotypically mature CD1a−CD27+
population. Both observations indicate a diminished T-cell
potential of HSPC following cytotoxic therapy.
Nevertheless, we could show the generation of functional,
mature T-cells from HSPC from patients in remission, albeit
with lower cell numbers as compared to younger healthy
sources. Combining cell yield data (before feeder expansion)
with the number of CD34+ cells that could be isolated from
patients or healthy donors, the minimum number of T-cells
that we can generate is 2.2 x 105/kg from AML patients (up to
1.99 x 108/kg), 61.6 × 106 from patients in remission (up to
1.92 x 109/kg) and 6.21 × 108 from healthy donors (up to 1.25
x 1011/kg). With CAR T-cells, as low as 1.5 × 105 cells per
kilogram of bodyweight have been injected into patients,
showing expansion, persistence and disease eradication,44 sug-
gesting our final cell numbers may be sufficient.
In acute myeloid leukemia, a complete remission can be
achieved in roughly 50% of patients with the classical 7 + 3
chemotherapy regimen,45 and even in this group the chance of
relapse is high (40 – 75%). Current treatment options for
relapsed or refractory AML only offer a bridge-to-
transplantation since no other curative option has been found
yet. In primary or secondary refractory AML patients, and
patients at risk for relapse, T-cell-based immunotherapy could
be a new treatment option, potentially even replacing HSCT. In
this setting, HSPC needs to be isolated from blood or bone
marrow with a high AML blast percentage. This is similar to
CD19 CAR T-cell therapy in refractory ALL patients, where
T-cells need to be isolated from peripheral blood containing
high numbers of malignant blasts.46 Therefore, we evaluated
the feasibility to generate TA-specific T-cells starting with
HSPC from leucapheresis, PB, or BM samples from AML
patients at diagnosis, who, like refractory patients, have
a high number of circulating leukemic cells. We selected
AML patients with a CD34-negative AML, as LSC are predo-
minantly CD34+.47,48 However, as there has been controversy
about the LSC immunophenotype,49 it might be necessary to
perform extensive genetic analyses before reintroducing our
T-cells back into the patient, to make sure no leukemic cells
are present. On the other hand, a study by Ruella et al.50
showed that in CD19 CAR-T treatment of B-ALL, presence
of rare leukemic blasts (<0.01%) at the time of infusion did not
correlate with relapse rate or time to relapse, indicating that
presence of a small amount of leukemic cells in the infusion
product not necessarily leads to relapse.
Patient cells usually need to be cryopreserved for practical
reasons in the course of treatment (e.g. before myeloablative
chemotherapy). Therefore, we investigated the effect of cryo-
preservation and thawing on the in vitro T-cell generation
process. In stem cell transplantation clinical practice, stem
cells are often cryopreserved (CB and autologous stem cell
products) and thawed before infusion. The reconstitutive
capacity of HSPC, cryopreserved for more than a decade,
has been evidenced by in vitro assays for CB51 and BM52
HSPC. More extensive in vivo assays in immunodeficient
mice demonstrated repopulation features of CB HSPC cryo-
preserved for up to 23.5 years, with multi-lineage engraftment
in mice at engraftment levels comparable with those reported
for fresh HSPC.51,53 Patient studies investigating the effect of
cryopreservation of HSPC from different sources (CB, mPB,
and BM) suggest that cryopreserved cells are not inferior to
freshly collected cells at different outcomes measured, includ-
ing engraftment rates, overall survival and GVHD.54,55 Our
study showed small but irrelevant differences between fresh
and cryopreserved samples. These results suggest it would be
possible to harvest stem cells from patients before exposing
them to detrimental effects of chemotherapy, and cryopreser-
ving these HSPC for later in vitro T-cell generation. In vitro
generated TA-specific T-cells can then be used as a treatment
strategy to eliminate LSC and thereby minimal residual dis-
ease in a patient in remission.
Even in the current CAR-T era, research into TCR-directed
therapy is indispensable. TCR, as opposed to CAR, recognize
intracellular antigens, making them able to recognize a larger
array of potential targets, which are also less prone to antigen
escape.13 TCR targets can be tumor-specific antigens, such as
mutated (neo)antigens exclusively expressed by tumor cells or
antigens re-expressed after embryogenesis, or tumor-
associated antigens (TAA). TAA, such as WT1, are self-
antigens overexpressed by tumor cells. TAA-specific TCR
can be induced in an allo-reactive setting,56 circumventing
negative selection processes in the thymus. Moreover, affinity-
enhancement of TCR has made it possible to optimize the
affinity of self-antigen reactive TCR,57,58 since receptor affi-
nities for self-antigen are generally low, even in an allo-
setting. Direct comparisons of TCR and CAR with similar
affinities have revealed a greater sensitivity in favor of
TCR.59,60
The benefits of using the OP9-DL1 co-culture system to
generate TCR-transduced T-cells are two-fold. On the one
hand, we generate T-cells with a single TA-specific TCR and
no endogenous TCR, circumventing the possibility of inducing
toxicity, as seen when introducing a transgenic TCR in PBL that
already express an endogenous TCR.20,21 Furthermore, we show
here that HSPC-derived TA-specific T-cells are more functional
against TA-expressing target cells, when compared to PBL-
derived TA-specific T-cells. This confirms our previous data,
where we have shown that this is due to higher TA-specific
TCR expression on transduced HSPC.28 On the other hand, we
generate T-cells with a favorable TSCM phenotype, believed to
be of optimal functionality and longevity in vivo, as opposed to
end-stage phenotype T-cells generated with extensive in vitro
culture protocols.22,61 On top of that, PD-1 expression is low,
even when cells are repeatedly stimulated with the agonist
peptide. This is in contrast to the article by Bucks et al., describ-
ing the upregulation of PD-1 expression after chronic antigen
exposure.39 In our model, repeated stimulation with the cognate
peptide at the CD4+CD8+ DP stage of T-cell maturation leads
to agonist selection instead of exhaustion.28 As we expect our
T-cells to expand in vivo after injection, we opt to inject them
before in vitro feeder expansion, to avoid extensive culture and
skewing toward TEM/TTE phenotypes. Since functionality is not
enhanced by multiple rounds of agonist peptide stimulation
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(before polyclonal feeder expansion), we would opt to do one
round of agonist peptide stimulation before injection, as these
cells show a favorable phenotype resembling mostly TN/TSCM.
As our in vitro culture protocol is a universal protocol, the
utilized TCR is interchangeable and not restricted to a certain
target. Hence, any high-affinity TCR can be isolated or
designed and used for the transduction of T-cell precursors
and subsequent generation of TA-specific T-cells. Moreover,
our group has previously shown that it is also possible to
generate CAR T-cells from HSPC using the OP9-DL1 co-
culture system.29 The resulting CAR+ T-cells were
CD3−TCRαβ−, and the endogenous TCR loci not rearranged,
excluding the possibility of alloreactivity. In the event that
a suitable target surface antigen for AML is found, we can use
the same clinically relevant HSPC sources as mentioned in
this paper to generate CAR T-cells expressing only the CAR
and no endogenous TCR.
We have shown here that it is feasible to generate TA-
specific T-cells from HSPC from adult healthy donors and
patients. We believe these T-cells could be of use as a very
valuable form of patient-tailored T-cell immunotherapy, after
being submitted to further extensive preclinical analyses.
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